Background: This study explored associations of genetic variants in the fetuin B (FETUB) locus with intrahepatic triglyceride (IHTG) content. Methods: Four tagging single-nucleotide polymorphisms (SNPs) of the FETUB locus and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 and transmembrane 6 super family member 2 (TM6SF2) rs58542926 were genotyped in 418 obese Chinese adults in whom serum FETUB and IHTG were measured. Results: Subjects carrying the minor G allele for FETUB rs4686434 (AG/GG) had lower serum FETUB levels (mean [AESD] 3.89 AE 1.36 vs 4.22 AE 1.46 μg/mL; P = 0.021) and IHTG content (12.7 AE 9.4% vs 14.6 AE 9.8%; P = 0.045) than their controls (AA), whereas IHTG content was higher in those carrying the minor G allele for PNPLA3 rs738409 (CG/GG) than in their controls (CC; 14.5 AE 10.1% vs 12.0 AE 8.6%; P = 0.012). After adjusting for potential confounders, IHTG content was lower in carriers of the minor G allele for FETUB rs4686434 (AG/GG vs AA, β −2.27 AE 0.91, P = 0.012), but was higher in carriers of the minor G allele for PNPLA3 rs738409 (CG/GG vs CC, β 2.65 AE 0.97, P = 0.006). There was a significant joint effect between FETUB rs4686434 and PNPLA3 rs738409 on IHTG content, with increasing genetic risk score (counting the risk allele of A in rs4686434 and G in rs738409) being associated with higher IHTG content (β 1.85 AE 0.48, P <0.001). Conclusions: Carrying the minor G allele for FETUB rs4686434 was significantly associated with decreased IHTG content and may affect hepatic triglyceride accumulation in individuals at high risk of non-alcoholic fatty liver disease.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, with prevalence rates of around 20%-30% in Western countries and 5%-18% in Asia. 1 Non-alcoholic fatty liver disease has been become a public health challenge because of its consequences not only for chronic liver disease, but also for extrahepatic diseases, such as type 2 diabetes mellitus (T2DM) and cardiovascular disease. [2] [3] [4] Fetuin B (FETUB) is a member of the cystatin superfamily of cysteine protease inhibitors and shares 22% homology with fetuin A, which has been found to be associated with NAFLD. 5 Meex et al. 6 reported that FETUB was increased in humans with liver steatosis and patients with T2DM, that it impaired insulin action in myotubes and hepatocytes, and caused glucose intolerance in mice. Zhu et al. 7 recently reported that serum FETUB concentrations were increased in subjects with NAFLD and suggested a potential association between FETUB and NAFLD.
Although in most existing literature NAFLD was generally evaluated by hepatic ultrasonography, quantitative data of intrahepatic triglyceride (IHTG) content may be a marker to assess the severity of liver steatosis. By using linear regression analyses with adjustment for potential confounding factors, we recently found that IHTG content was independently and positively correlated with serum FETUB concentrations (β = 0.015, P = 0.045). 8 However, associations of genetic variations in the FETUB locus (encoding the FETUB protein) with IHTG content have not been reported.
Genome-wide association studies (GWAS) have identified several variants among the patatin-like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 super family member 2 (TM6SF2) loci that are significantly associated with NAFLD in multiethnic populations. Romeo et al. 9 first reported that the G allele in a single nucleotide polymorphism (SNP) of PNPLA3 rs738409 is associated with increased hepatic fat levels and confers susceptibility to NAFLD. More recently, based on an exome-wide association study, Kozlitina et al. 10 reported that the T allele in TM6SF2 rs58542926 is associated with increased liver fat content and causally contributes to NAFLD. Many subsequent studies confirmed these associations in different ethnic populations. [11] [12] [13] [14] Some further reported a joint effect of PNPLA3 rs738409 with TM6SF2 rs58542926 on NAFLD. 12, 13 However, NAFLD was evaluated by hepatic ultrasonography in many of these studies, which cannot assess the severity of liver steatosis. 11, 12 Therefore, studies on different ethnic populations, especially with quantitative data on the degree of hepatic steatosis, are needed to validate associations between genetic variants among PNPLA3 and TM6SF2 loci and NAFLD.
In the present study on 418 community-living Chinese adults with central obesity who underwent intrahepatic triglyceride (IHTG) content measurements by magnetic resonance spectroscopy (MRS), we first aimed to explore potential associations between common genetic variants in the FETUB locus and IHTG content. Second, we wanted to determine whether PNPLA3 rs738409 or TM6SF2 rs58542926 contribute to IHTG content in obese Chinese populations. Third, we wanted to determine whether common genetic variants in the FETUB locus affect IHTG content jointly with PNPLA3 rs738409 or TM6SF2 rs58542926.
Methods

Study design and participants
In 2011, 1523 subjects aged ≥40 years living in Lianqian community, Xiamen, China, with central obesity (waist circumference >90 cm for men and >80 cm for women) were recruited for the baseline examination of our designed cohort study. Details on subject sampling, recruitment, and evaluation have been published previously. 15, 16 A random subgroup of 428 subjects underwent IHTG measurement by MRS. Of these, 418 subjects with complete data for clinical measurements were successfully genotyped and used in the present study (Fig. 1 Figure 1 Selection of study subjects. IHTG, intrahepatic triglyceride; FETUB, fetuin B; MRS, magnetic resonance spectroscopy.
Measurements
Face-to-face interviews, measurement of clinical characteristics, blood sample collection and biochemical measurements have been described previously. 15, 16 Intrahepatic triglyceride content was determined by an experienced radiologist using MRS ( 1 H MRS, 3.0-T Avanto; Siemens, Erlangen, German). Images of a sagittal, coronal, and axial cube (volume 2 cm 3 ) in the right lobe of the liver were acquired. Quantification of the spectra (water and methylene resonances) was performed as described previously. 17 Areas of resonance from water protons and methylene groups in fatty acid chains were obtained with a time domain non-linear fitting routine using Syngo MR B15V software (Siemens). The percentage IHTG content was calculated as the ratio of the area under the resonance of peak for methylene groups in fatty acid chains of IHTG to the combined area under the resonance peaks for both methylene groups and water.
Measurement of serum FETUB concentrations
Serum FETUB concentrations were measured by ELISA (Abcam, Cambridge, UK). The sensitivity of the assay was 4 ng/mL and the linear range of the standard was 4-50 ng/mL. The intra-and interassay coefficients of variation were < 10% and < 12%, respectively.
Selection of tagging SNPs for the FETUB locus
A genomic area on human chromosome 3q27. (Fig. 2) . Seven HapMap SNPs were present and exhibited HardyWeinberg equilibrium (HWE). We focused on the common SNPs only and found that six SNPs showed minor allele frequencies (MAFs) ≥0.05 and were genotyped in ≥50% of HapMap individuals. Based on Tagger analysis using Haploview 4.2 software (http://hapmap.ncbi. nlm.nih.gov/, accessed 24 February 2016), four SNPs were selected as tagging SNPs covering all the other common SNPs within the locus with r 2 > 0.8 (100% coverage), namely rs3733159 (T/G), rs4686434 (A/G), rs1047115 (A/C), and rs6785067 (G/A).
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using a commercial DNA isolation kit (QIAamp DNA Blood Midi Kit; Qiagen, Beijing, China). The four FETUB tagging SNPs and PNPLA3 rs738409 and TM6SF2 rs58542926 were genotyped by polymerase chain reaction (PCR), which was performed using an annealing temperature of 65.0 C on ABI3730XL DNA Analyzer (Applied Biosystems, Foster, CA, USA). The following primer pairs were used to genotype the six SNPs: rs3733159, CCC AAA ATG TT-3 0 (forward) and 5 0 -CCG TGG AGA TCA AGA TCA GC-3 0 (reverse). Genotyped sequences were analyzed using Sequencing Analysis Software Version 5.2 (Applied Biosystems).
Statistical analysis
Power calculations for associations of tested SNPs with high IHTG content were conducted using Quanto (version 1.2.4; University of Southern California, Los Angeles, CA, USA). Among all the subjects, 139 were defined as having a high IHTG content (i.e. in the third tertile) and 279 were controls (i.e. in the first and second tertiles of IHTG content). Two-sided P < 0.05 and a log-additive genetic model were used. Under these assumptions, for FETUB rs3733159, rs6785067, PNPLA3 rs738409, and TM6SF2 rs58542926, of which the minor alleles may show an increased likelihood of high IHTG content, power only for those with an MAF >20% and odds ratio (OR) >1.7, such as PNPLA3 rs738409, was sufficient (power >0.8; see Table S1 , available as Supplementary Material to this paper). Powers for FETUB rs4686434 and rs1047115, of which the minor alleles may show a decreased likelihood of high IHTG content (OR~0.5 and MAF >10%), were approximately sufficient (Table S2) .
Data are presented as the mean AE SD for continuous variable and as the number and percentage for categorical variables. Skewness and kurtosis tests for normality of IHTG content revealed that IHTG content followed an approximately normal distribution. Differences between subjects (categorized by tertiles of IHTG content) were analyzed using one-way analysis of variance (ANOVA) for continuous variable and Chi-squared tests for categorical variables. Hardy-Weinberg equilibrium was tested using Chi-squared tests ( 
2 ) between the tested SNPs was analyzed using MIDAS v1.0 (http://www.genes.org.uk/software/midas, accessed 24 February 2016) . 18 Associations between the genotypes and IHTG content, high IHTG content, and serum FETUB concentrations were evaluated by coding the genotype with an additive model of inheritance (i.e. the genotype is coded with 0, 1, or 2 corresponding to the number of minor alleles carried by each subject).
Multivariable linear regression was used to explore the associations of tested SNPs with IHTG content. Multivariable logistic regression was used to calculate adjusted ORs and 95% confidence intervals (CIs) of tested SNPs for high IHTG content (defined as the third tertile of IHTG content) versus the first and second tertiles of IHTG content with adjustment for potential confounders. For both multivariable linear regression and multivariable logistic regression, age and sex were adjusted for in Model 1. Model 2 was adjusted for all variables in Model 1 plus education level, smoking and drinking habits, regular physical exercise, adiposity (waist circumference), systolic and diastolic blood pressure (DBP and SBP, respectively), triglycerides (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C). In each model, genotypes were presented as subjects with one or two minor alleles versus those with no minor alleles. Because the minor G allele for FETUB rs4686434 shows a protective effect on IHTG content, the genetic risk score for FETUB rs4686434 and PNPLA3 rs738409 was calculated by counting the risk allele A in rs4686434 and the risk allele G in rs738409.
Based on screening four non-linked tagging SNPs for FETUB in parallel, P < 0.0125 was considered statistically significant according to Bonferroni correction for multiple comparisons. All statistical analyses were performed using Stata14.0 (StataCorp, College Station, TX, USA).
Results
Demographic and clinical characteristics stratified by IHTG tertiles
Of the 418 subjects, 311 (74.4%) were female. The mean age of men and women was 53.6 AE 6.5 and 53.0 AE 7.1 years, respectively (P = 0.418). Figure 3 shows the distribution of IHTG content for all subjects in the study. Subjects were divided into three groups according to IHTG content: Tertile 1, 4.9 AE 1.8%; Tertile 2, 11.2 AE 2.3%; and Tertile 3, 25.1 AE 7.7%. Table 1 shows differences in demographics, lifestyle habits, and clinical characteristics of subjects stratified according to IHTG tertile. Generally, with increasing levels of IHTG, subjects were more likely to be men and to have a significantly higher body mass index (BMI), waist circumference, DBP, TG, fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR), and lower HDL-C levels. There was no statistically significant difference in age, body fat rate, SBP, TC, low-density lipoprotein cholesterol (LDL-C), or fasting glucose among the IHTG tertiles.
Genotype distributions and allele frequencies
All four FETUB tagging SNPs (rs3733159, rs4686434, rs1047115, and rs6785067), as well as PNPLA3 rs738409 and TM6SF2 rs58542926, obeyed HWE (P > 0.05). The MAFs of the six SNPs tested ranged from 4.7% to 46.9% (Table 2) 
showed that the observed genetic linkage between the tested SNPs was low or moderate (r 2 0.05-0.45).
Associations of FETUB SNPs with serum FETUB concentrations
As indicated in Table 3 , the minor G allele for FETUB rs4686434 and the A allele for FETUB rs6785067 were significantly associated with lower serum FETUB concentrations, whereas the other two FETUB SNPs tested (rs3733159 and rs1047115) did not show significant association with serum FETUB concentrations.
Associations of tested SNPs with IHTG content
For FETUB rs4686434, subjects with one or two minor alleles (AG/GG) had lower IHTG content than those with no minor alleles (AA; 12.7 AE 9.4% vs 14.6 AE 9.8%, respectively; P = 0.045; Fig. 4a ; Table 2 ). Subjects with one or two minor alleles (CG/GG) in PNPLA3 rs738409 had a higher IHTG content than those with no minor alleles (CC; 14.5 AE10.1% vs 12.0 AE 8.6%, respectively; P = 0.012; Fig. 4b ; Table 2 ). Multivariable linear regression analyses with adjustment for potential confounders revealed that there was a negative association with IHTG content in subjects carrying the minor G allele for FETUB rs4686434 whereas there was a positive association in those carrying the minor G allele for PNPLA3 rs738409; the regression coefficients (AESEM) were − 2.27 AE 0.91 Unless indicated otherwise, data are given as the mean AESD or as n (%), with all percentages being column percentages. BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; IHTG, intrahepatic triglyceride; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
(P = 0.012) and 2.65 AE 0.97 (P = 0.006), respectively (Table 4 , Model 2). Further adjustment for rs4686434 and rs738409 in Model 2 did not significantly alter the regression coefficients: −2.37 AE 0.90 (P = 0.009) and 2.74 AE 0.96 (P = 0.005), respectively. There was no significant association between the other SNPs tested (FETUB rs3733159 and rs6785067 and TM6SF2 rs58542926) and IHTG content.
Associations of tested SNPs with high IHTG content
Subjects with one or two minor alleles (AG/GG) in rs4686434 also had a lower prevalence of high IHTG content than their controls (AA; 26.9% vs 38.4%; P = 0.013). However, subjects with one or two minor alleles (CG/GG) in rs738409 had a higher prevalence of high IHTG content (36.4% vs 26.5%; P = 0.047; Table 2 ). Table 4 also shows the adjusted ORs with associated 95% CIs of the different genotypes for high IHTG content, obtained using multivariable logistic regression analyses with adjustment for potential confounding factors. Similar to the results of the multivariable linear regression analyses, subjects with one or two minor G alleles in FETUB rs4686434 were associated with a lower likelihood of high IHTG content, whereas those with one or two minor G alleles in PNPLA3 rs738409 were associated with a higher likelihood; the adjusted ORs were 0.53 (95% CI 0.34-0.83; P = 0.006) and 1.72 (95% CI 1.06-2.81; P = 0.029), respectively (Table 4 , Model 2). There was no significant association of the other SNPs tested (FETUB rs3733159 and rs6785067 and TM6SF2 rs58542926) with high IHTG content. Although the minor C allele for FETUB rs1047115 showed a trend for lower IHTG content, it was not statistically significant according to Bonferroni corrections.
The association results for the tested SNPs with IHTG content from allelic models were similar to those from genotype models (Table S3 ). The G allele for PNPLA3 rs738409 was significantly associated with increased IHTG content (β = 2.00 AE0.62; P = 0.001) with adjustment for potential confounding factors. The G allele for FETUB rs4686434 was not significantly associated with IHTG content after adjusting for multiple comparisons (β = −1.56 AE 0.79; P = 0.048), but its association with high IHTG content was marginally significant (OR 0.61; 95% CI 0.41-0.89; P = 0.013).
Joint effect of FETUB rs4686434 and PNPLA3 rs738409 on IHTG content
Because carriers of the minor G allele for FETUB rs4686434 show a significant negative association with IHTG content, whereas those with the minor G allele for PNPLA3 rs738409 show a positive association, we evaluated whether there was a joint effect between them. The genetic risk score was calculated by counting the risk allele A in rs4686434 and the risk allele G in rs738409. As shown in Fig. 4c , a higher genetic risk score was significantly associated with higher IHTG content (11.9 AE 8.9%, 12.5 AE 9.1%, 15.1 AE 9.8%, and 16.0 AE 11.1% for genetic risk scores of 0/1, 2, 3, and 4, respectively; P = 0.028). By using both multivariable linear regression and logistic regression analyses with adjustment for potential confounding factors, a higher genetic risk score was found to be significantly associated with elevated IHTG content (β = 1.85 AE 0.48; P < 0.001) and increased likelihood of high IHTG content (OR 1.52; 95% CI 1.19-1.95; P = 0.001; Table 4 ).
Discussion
To the best of our knowledge, the present study is probably the first to identify that among obese Chinese adults, carriers of the minor G allele for FETUB rs4686434 are significantly associated with decreased serum FETUB concentrations and lower IHTG content. We also confirmed that PNPLA3 rs738409, but not TM6SF2 rs58542926, was significantly associated with IHTG content in this population. Moreover, we calculated a genetic risk score by using two SNPs (FETUB rs4686434 and PNPLA3 rs738409) and found that a higher genetic risk score was significantly associated with increased IHTG content.
Fetuin B was identified as a second member of the fetuin family, the cystatin superfamily of cysteine protease inhibitors, in 2000. 19 Denecke et al. 20 found that although FETUB shares 22% homology with fetuin A, the function of FETUB is not identical to that of fetuin A. Fetuin A has been found to be causally related to NAFLD, 5 but little is known about the role of FETUB in the pathogenesis of NAFLD. Meex et al. 6 reported that patients with liver steatosis had increased FETUB concentrations compared with their controls. It was further reported that serum FETUB concentrations increased in subjects with NAFLD. 7 The FETUB gene encodes the FETUB protein and is located on human chromosome 3q27.3 and has eight exons. The FETUB rs4686434 SNP, an intron variant, is characterized by a G-to-A substitution. In the present study, subjects carrying the minor G allele for FETUB rs4686434 had lower serum FETUB concentrations than their controls. In a recent study, we also found that subjects with higher serum FETUB concentrations had a significantly higher prevalence rate of NAFLD and higher IHTG content and that the IHTG content was independently and positively correlated with serum FETUB concentrations. 8 Therefore, it is interesting that in the present study subjects carrying the minor G allele for FETUB rs4686434 had lower serum FETUB concentrations and decreased IHTC content than their controls. After Unless indicated otherwise, data are given as the mean AE SD. *Serum FETUB concentrations were adjusted for age and sex. adjusting for potential confounding factors (even the other tested genetic variants, such as PNPLA3 rs738409), we identified that the variant in FETUB rs4686434 was significantly and independently associated with IHTG content. So, the novel finding of the present study is that carrying the G allele for FETUB rs4686434 may affect hepatic TG accumulation in obese Chinese adults who are at high risk of NAFLD. In addition, we found a trend for carrying the C allele for FETUB rs1047115, another SNP characterized by a C-to-A substitution, to be associated with decreased IHTG content, although this association was not statistically significant after Bonferroni corrections. How carrying the G allele for FETUB rs4686434 is likely to cause lower serum FETUB concentrations and decrease IHTG content is currently unknown. The rs738409 SNP of PNPLA3 was first identified by Romeo et al. 9 using GWAS as a genetic variant that contributes to hepatic fat levels and confers susceptibility to NAFLD. Subsequent studies have confirmed associations of this variant with hepatic fat content, elevated circulating liver enzyme levels, and liver injury. 11, [21] [22] [23] [24] In the present study, we consistently found that the G allele for rs738409 was significantly associated with greater severity of hepatic steatosis (IHTG content measured by MRS).
(a)
The protein encoded by PNPLA3 shows lipase activity against TG in hepatocytes, and a missense mutation in PNPLA3 decreases TG hydrolysis and promotes hepatic steatosis. 25, 26 The TM6SF2 SNP rs58542926 has recently been identified and validated as another genetic variant associated with NAFLD, 10 progression of NAFLD, [27] [28] [29] and plasma cholesterol, TG, and LDL-C levels, 30, 31 although the functions of TM6SF2 protein are currently unknown. We failed to find a significant association between the TM6SF2 rs58542926 variant and IHTG content in obese Chinese adults in the present study, which is inconsistent with the results of a previous study in the Chinese population even though our sample size (n = 418) and allele frequencies (MAF = 0.061) were comparable to those in the previous study (n =766, MAF = 0.072). 12 However, it should be noted that NAFLD was evaluated by hepatic ultrasonography in the previous study and degree of liver steatosis was not assessed. 12 Holmen et al. 30 found that TM6SF2 rs58542926 C allele carriers 33 more studies are warranted to validate the association between the TM6SF2 rs58542926 variant and NAFLD with different diagnostic measurements in various ethnic populations.
Because we found both FETUB rs4686434 and PNPLA3 rs738409 were significantly associated with IHTG content in obese Chinese adults and the genetic linkage between them was low, we assessed whether there was a joint effect between these two variants on IHTG content. We found a higher genetic risk score (counting the risk allele A in rs4686434 and the risk allele G in rs738409) was significantly associated with higher IHTG content. Although many others confirmed a joint effect between PNPLA3 rs738409 and TM6SF2 rs58542926 in different populations, 12, 13 we are probably the first to report a significant joint effect between FETUB rs4686434 and PNPLA3 rs738409 on IHTG content in obese Chinese adults. Therefore, the results of the present study may have implications on NAFLD classification and diagnosis based on this joint effect among different risk alleles.
The present study has a few limitations. One of the major limitations of the study was that our subjects all had central obesity with a relatively higher IHTG content. Approximately 81% of subjects were at high risk of NAFLD (defined as IHTG content ≥5.5%), 34 and we may not have truly estimated the genetic associations of the tested variants among the FETUB, TM6SF2, and TM6SF2 loci with IHTG content. Therefore, the findings cannot be generalized to other populations, especially lean subjects. Another major limitation of the study was that the sample size was relatively small and may not have sufficient power to find more significant associations between these candidate variants and IHTG content. Third, the unbalanced sex ratio (only 25% of subjects were male) in the present study may spark concerns of different associations for males and females. Therefore, a study with a larger sample size, especially a prospective cohort study design, should be conducted to validate these associations, including stratified analyses by gender. Fourth, we cannot rule out the possibility of reverse causality between serum FETUB concentrations and IHTG content due to our cross-sectional study design. Finally, an independent cohort, especially including lean subjects, to validate the present findings was not available to us. Conversely, the present study does have a few strengths. First, we quantified hepatic steatosis by IHTG content using non-invasive MRS. Second, for testing independent associations between genetic variants and IHTG content in the multivariable regression analyses, we adjusted for many more potential confounders than previous studies.
In conclusion, the present study has demonstrated, for the first time, that the minor G allele for FETUB rs4686434 was significantly associated with lower serum FETUB concentrations and decreased IHTG content in obese Chinese adults, and may therefore affect the hepatic TG accumulation in these high-risk individuals. In addition, we found a significant joint effect between FETUB rs4686434 and PNPLA3 rs738409 on IHTG content. These findings underscore the role of FETUB rs4686434 in the pathogenesis of hepatic steatosis. Future studies should be conducted to validate our findings in different ethnic populations, especially in non-obese subjects, with a larger sample size, and elucidate the mechanisms by which this mutation affects liver fat accumulation.
